← Back to Search

Cytokine

CYT107 for COVID-19 (ILIAD-7-US-O Trial)

Phase 2
Waitlist Available
Led By Marcel van den Brink, MD, PhD
Research Sponsored by Revimmune
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month or hd (whichever occurs first)
Awards & highlights

ILIAD-7-US-O Trial Summary

This trial looks at whether a drug called CYT107 can help people with COVID-19 who have low levels of a type of white blood cell called lymphocytes.

Eligible Conditions
  • COVID-19
  • Coronavirus
  • Lymphocytopenia

ILIAD-7-US-O Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one month
This trial's timeline: 3 weeks for screening, Varies for treatment, and one month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Improvement of the absolute lymphocyte count (ALC) of lymphopenic (ALC≤1000/mm3) COVID-19 infected participants out to approximately 30 days following initial Study drug administration or Hospital discharge (HD), whichever occurs first
Secondary outcome measures
All-cause mortality through day 45 compared to placebo arm
CD4+ and CD8+ T cell counts compared to placebo arm
Frequency of re-hospitalization through day 45 compared to placebo arm
+11 more
Other outcome measures
Safety assessment through incidence and scoring of grade 3-4 adverse events

ILIAD-7-US-O Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: CYT107 TreatmentExperimental Treatment1 Intervention
Intramuscular (IM) administration of CYT107 twice a week for 3 weeks
Group II: Saline controlPlacebo Group1 Intervention
Intramuscular (IM) placebo (normal saline) at the same frequency

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterOTHER
1,933 Previous Clinical Trials
585,612 Total Patients Enrolled
6 Trials studying COVID-19
453 Patients Enrolled for COVID-19
RevimmuneLead Sponsor
9 Previous Clinical Trials
171 Total Patients Enrolled
4 Trials studying COVID-19
99 Patients Enrolled for COVID-19
M.D. Anderson Cancer CenterOTHER
2,967 Previous Clinical Trials
1,804,792 Total Patients Enrolled
17 Trials studying COVID-19
76,517 Patients Enrolled for COVID-19

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
The LancetJournal
Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study
Zhou, Fei, Ting Yu, Ronghui Du, Guohui Fan, Ying Liu, Zhibo Liu, Jie Xiang, et al.. 2020. “Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study”. The Lancet. Elsevier BV. doi:10.1016/s0140-6736(20)30566-3.
JamaJournal
Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus–infected Pneumonia in Wuhan, China
Wang, Dawei, Bo Hu, Chang Hu, Fangfang Zhu, Xing Liu, Jing Zhang, Binbin Wang, et al.. 2020. “Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus–infected Pneumonia in Wuhan, China”. Jama. American Medical Association (AMA). doi:10.1001/jama.2020.1585.
clinicaltrials.govStudy
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )
2020. "InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04426201.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top